Jia Liu, PhD

Research Program: Cancer Biology Faculty Rank: Assistant Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Microbiology & Immunology Faculty

Cancer Research Interest

• Research Interest Statement: The focus of Dr. Jia Liu's research is to use the knowledge of the coordinated host intrinsic and innate immunity for thedevelopment of cancer immunotherapy. I use myxoma virus (MYXV), a poxvirus only causing infectious disease in rabbitsas the model organism; particularly I study the immunosuppressive tumor environment such as the one presented inovarian cancer (OC) and repurpose oncolytic MYXV for immunotherapy of OC. In this process our work also provide in depthunderstanding of the immunosuppressive tumor environment. We discovered an unusual STAT3 signaling pathway thatplays a critical role for the immunosuppressive myeloid and tumor cells. By using immunotherapeutic MYXV to disarmthese disease myeloid and tumor cells, we aim to provide novel treatment options for cancer patients.Our long-term goal is to improve understanding the cross talk between host intrinsic and innate immunity, so that itsactivation can be applied to facilitate the elimination of malignancy through immunotherapy.

Contact Information

• Email Address: JLIU4@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• River Valley Ovarian Cancer Alliance – AWD00053633
  “MYXOMA VIRUS COMPOSITIONS AND METHODS OF USE”
  Principal Investigator
  6/1/2019 – 6/30/2025
• NIH/Nat. Inst. of Allergy & Infectious Diseases – 1R01AI139106
  “Studies in Poxvirus Evasion of SAMD9 Pathway - Continuation”
  Principal Investigator
  1/1/2019 – 12/31/2024

Recent Publications

• Ledford A, Rodriguez A, Lipinski L, [et al., including Liu J]. Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma. Scientific reports. 2024 14(1):19474. PMID: 39198514. PMCID: PMC11358395.
• Wang S, Argikar UA, Chatzopoulou M, [et al., including Liu J]. Bioactivation and reactivity research advances - 2023 year in review. Drug metabolism reviews. 2024:1-38. PMID: 38963129.
• Wlodarski MW, Vlachos A, Farrar JE, [et al., including Liu JM]. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology. 2024 11(5):e368-e382. PMID: 38697731.
• Li J, Yang L, Song J, [et al., including Liu J]. Neurotensin accelerates atherosclerosis and increases circulating levels of short-chain and saturated triglycerides. Atherosclerosis. 2024:117479. PMID: 38423808. PMCID: PMC11088984.
• Mao X, Yan W, Mery D, [et al., including Liu J]. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. American journal of hematology. 2024. PMID: 38247315. PMCID: PMC10947864.
• Dai L, Goyal N, Liu J, [et al.]. Developing new ceramide analogs against non-small cell lung cancer (NSCLC). American journal of cancer research. 2024 14(1):86-96. PMID: 38323290. PMCID: PMC10839310.
• Liu J, Lavie CJ, Park YM, Bagiella E. Geographic variation and trends in prevalence of obesity among US adolescents, 2016-2021. Public health. 2023 223:128-130. PMID: 37634452.
• Khojasteh SC, Argikar UA, Cheruzel L, [et al., including Liu J]. Biotransformation research advances - 2022 year in review. Drug metabolism reviews. 2023:1-42. PMID: 37737116.
• Wang S, Argikar UA, Cheruzel L, [et al., including Liu J]. Bioactivation and reactivity research advances - 2022 year in review‡. Drug metabolism reviews. 2023:1-34. PMID: 37608698.
• Nassiri F, Patil V, Yefet LS, [et al., including Liu J]. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature medicine. 2023. PMID: 37188783. PMCID: PMC10287560.
• LaFargue CJ, Amero P, Noh K, [et al., including Liu J]. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nature communications. 2023 14(1):2407. PMID: 37100807. PMCID: PMC10133315.
• Delamonica B, Davalos L, Larijani M, [et al., including Liu J]. Evolutionary potential of the monkeypox genome arising from interactions with human APOBEC3 enzymes. Virus evolution. 2023 9(2):vead047. PMID: 37577211. PMCID: PMC10422979.
• Corken A, Ware J, Dai J, [et al., including Liu J]. Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study. Kidney360. 2022 3(12):2036-2047. PMID: 36591354. PMCID: PMC9802560.
• Campos S, Matulonis U, Berlin S, [et al., including Liu J]. A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. International journal of clinical oncology. 2022 27(12):1881-1890. PMID: 36344654.
• Conrad SJ, Raza T, Peterson EA, [et al., including Liu J]. Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages. PLoS pathogens. 2022 18(9):e1010316. PMID: 36103568. PMCID: PMC9473615.
• Geng T, Chang X, Wang L, [et al., including Liu J]. The association of genetic susceptibility to smoking with cardiovascular disease mortality and the benefits of adhering to a DASH diet: The Singapore Chinese Health Study. The American journal of clinical nutrition. 2022 116(2):386-393. PMID: 35551603. PMCID: PMC9348979.
• Li D, Yu X, Kottur J, [et al., including Liu J]. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. 2022. PMID: 35525905. PMCID: PMC9189076.
• Araujo N, Sledziona J, Noothi SK, [et al., including Liu J]. Tumor Suppressor Par-4 Regulates Complement Factor C3 and Obesity. Frontiers in oncology. 2022 12:860446. PMID: 35425699. PMCID: PMC9004617.
• Arthur JM, Forrest JC, Boehme KW, [et al., including Liu J]. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PloS one. 2021 16(9):e0257016. PMID: 34478478. PMCID: PMC8415618.
• Wang R, Kumar B, Bhat-Nakshatri P, [et al., including Liu J]. Aging-associated skeletal muscle defects in HER2/Neu transgenic mammary tumor model. JCSM rapid communications. 2021 4(1):24-39. PMID: 33842876. PMCID: PMC8028024.
• Tang B, Guo ZS, Bartlett DL, [et al., including Liu J]. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 26(9):2216-2230. PMID: 32019860. PMCID: PMC7723446.